Arcellx : Corporate Presentation July 2023

Corporate Presentation

July 2023

Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, that are based on our management's beliefs and assumptions and on information currently available to our management. All statements other than statements of historical facts contained in this presentation, including statements regarding the potential benefits, value, synergies and results that may be achieved through our collaboration with Kite; the anticipated payments that may be received by us in connection with the collaboration, including potential milestones and royalties; our and Kite's respective rights and obligations under the transaction agreements; expectations of our ability to benefit from Kite's capabilities, including operational, manufacturing and commercialization expertise and infrastructure; expected costs and expenses to be incurred and shared with Kite; our future financial condition and runway, results of operations, business strategy, milestones, team and operations, timelines, and prospects; the potential of and expectations regarding our product candidates, programs, platform and technology; the mission, plans and objectives of management and; industry trends, including changes in market opportunity, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "believe," "can," "contemplate," "continue," "could," "design," "estimate," "expect," "future," "goal," "imagine," "intend," "likely," "may," "mission," "might," "objective," "ongoing," "plan," "potential," "predict," "project," "should," "target," "united to," "will," or "would," or the negative of these terms or other similar expressions or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy and financial needs, and these statements represent our views as of the date of this presentation. We may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Information regarding certain risks, uncertainties and assumptions may be found in our filings with the Securities and Exchange Commission. New risk factors emerge from time to time and it is not possible for our management team to predict all risk factors or assess the impact of all factors on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this presentation.

This presentation discusses product candidates that are under preclinical or clinical evaluation and that have not yet been approved for marketing by the U.S.

Food and Drug Administration or any other regulatory authority. The presentation also includes select interim and preliminary results from an ongoing clinical trial as of specific data cutoff dates. Such results should be viewed with caution as final results may differ as additional data becomes available. Until finalized

SOLID

in a clinical study report, clinical trial data presented herein remain subject to adjustment as a result of clinical site audits and other review processes. No

TUMORS 90%

representation is made as to the safety or effectiveness of these product candidates for the use for which such product candidates are being studied.

This presentation also contains estimates and other statistical data made by independent parties or publicly available information, as well as other information based on our internal sources. These data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. We have not independently verified the accuracy or completeness of the data contained in these industry publications and other publicly available information. Accordingly, we makes no representations as to the accuracy or completeness of that data.

Arcellx Corporate Presentation | July 2023

2

Arcellx is a Different Kind of

Cell Therapy Company

Potential best-in-class therapy partnered with Kite, the global leader in cell therapy.

Scalable manufacturing and commercial footprint to support leadership

in a $12B+ market.

Sufficient capital to fund operations through 1H'25.

Reimagining Cell Therapy

Novel Synthetic Binding Domain

Single-infusion ddCAR

platform and

Dosable, controllable ARC-SparX platform

+

Positive Preliminary	Partnered Lead
Clinical Results	Program
Demonstrated 100%	Combining potential
overall response rate	best in class program
and deep durability in	with Kite's commercial
CART-ddBCMA	and manufacturing
multiple myeloma	expertise
Phase 1 study.
Pivotal study enrolling

ARC-SparX

Platform Potential

ACLX-001 Phase 1 clinical

trial in MM initiated in

2Q22

ACLX-002 Phase 1 clinical

trial in AML/MDS initiated in 4Q22

Built for

Success

Strong investor base

Exceptional team Wholly owned IP Well capitalized

Arcellx Corporate Presentation | July 2023

4

2022 Achievements and Future Milestones

2022 Achievements

IPO in February raising $142.3M

ddCAR- Presented Clinical Data Updates at ASCO and ASH

Raised $128.8M in upsized public offering

ddCAR- Initiated Phase 2 iMMagine-1 pivotal trial

ddCAR- Partnered lead clinical program with Kite, a Gilead company

ARC-SparX - Initiated ACLX-001 Phase 1 clinical trial in MM

ARC-SparX - Initiated ACLX-002 Phase 1 clinical trial in AML/MDS

Future Milestones	Anticipated
Timing
ddCAR - Complete enrollment in Phase 2	2H23
iMMagine-1 pivotal trial
ddCAR - Present long-term clinical and	2H23
median PFS data from Phase 1 clinical trial
ddCAR - Initiate iMMagine-2, earlier line	2H23
clinical trial
ARC-SparX - Present interim clinical data	2H23
from ACLX-001 in MM
ddCAR - Present interim data from Phase	1H24
2 pivotal trial
ddCAR- Anticipated BLA filing for the	1H25
treatment of BCMA

Arcellx Corporate Presentation | July 2023

5